As the randomized clinical trials to assess the effects of antisense oligonucleotide drugs targeting Lp(a) are in development, this might be a treatment option for very high-risk CAD patients with Lp(a)-hyperlipoproteinemia and metabolic disorders. The gene discussed is LPA; the disease is coronary artery disorder.